Biotech | September 09, 2021
Eirion Therapeutics mandates HTL Biotechnology to be its exclusive Botulinum API manufacturer.
HTL will build, validate and operate a botulinum manufacturing facility in the US
HTL will build, validate and operate a botulinum manufacturing facility in the US
In his previous assignment Perfetti was associated with Fabbrica Italiana Sintetici (F.I.S) as Chief Commercial Officer
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
Caspian Debt has in principle committed up to Rs 35 crores to SAMRIDH’s commercial debt investment pool
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Subscribe To Our Newsletter & Stay Updated
